Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
February 2012, Vol 3, No 1
February 2012, Vol 3, No 1
Regorafenib Extends Survival in Advanced CRC
By
Caroline Helwick
GI Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—The novel tyrosine kinase inhibitor (TKI) regorafenib, used as a single agent to treat treatment-refractory metastatic colorectal cancer (CRC), significantly improved survival and delayed disease progression in an international phase 3 trial presented at the 2012 Gastrointestinal Cancers Symposium.
Read Article
Promising Data for New DNA Stool Testing, at Low Cost
GI Cancers Symposium
February 2012, Vol 3, No 1
>San Francisco, CA—The “eradication” of colorectal cancer (CRC) may be a step closer, based on promising data for stool DNA testing, said David A. Ahlquist, MD, Mayo Clinic, Rochester, MN, at the 2012 Gastrointestinal Cancers Symposium.
Read Article
Building a National Patient Advocacy Network in Oncology
By
Rose Gerber
Patient Advocacy
,
Policies & Guidelines
February 2012, Vol 3, No 1
Read Article
Patient Advocacy: A Physician’s Perspective
By
Richard Frame, MD
Patient Advocacy
,
Policies & Guidelines
February 2012, Vol 3, No 1
I never thought it would happen in the United States, but it has. We are critically close to running out of some chemotherapy drugs. It came as a shock to all of us, when we realized how severely the problem of drug shortages has started to affect our patients. The following case is but one example.
Read Article
Paying for Quality: Increasing Shift Toward Value-Based Healthcare
Health Policy
,
Policies & Guidelines
February 2012, Vol 3, No 1
On November 30, 2011, the Office of the Inspector General (OIG) of the US Department of Health and Human Services issued an advisory opinion (No. 11-18) to the web-based physician practice service provider athenahealth, tacitly approving the company’s new online service athenaCoordinator.
Read Article
Mammography Use Increases When Copays Are Dropped
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
February 2012, Vol 3, No 1
San Antonio, TX—When copayments were eliminated, annual screening mammography rates among insured rural women improved significantly, researchers from Duke University Comprehensive Cancer Center reported at the 2011 CTRC AACR San Antonio Breast Cancer Symposium.
Read Article
The Health Burden of Multiple Myeloma: Subcutaneous Bortezomib a New, Convenient Route of Administration Option
By
Rhonda Williams
Cancer Drugs
,
Personalized Medicine
February 2012, Vol 3, No 1
In 2011, the American Cancer Society projected there would be 20,520 cases of newly diagnosed multiple myeloma (MM) and 10,610 deaths from the disease that year.
1
MM is an incurable hematologic cancer marked by great heterogeneity, in terms of its biology and clinical course.
Read Article
Future Directions in Myeloma
By
Caroline Helwick
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
With so many new myeloma drugs of various classes in the pipeline, “myeloma is going to become a chronic illness, with sustained complete responses in a significant fraction of patients,” according to Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute and Harvard Medical School, Boston.
Read Article
Molecular Profiling for Stage II Colon Cancer
GI Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—Approximately 80% of patients with stage II colon cancer will be cured by surgery alone, but 20% will still relapse. Oncologists struggle with the question of which patients could benefit from adjuvant chemotherapy to reduce this risk, and which patients can be safely observed, without further treatment.
Read Article
The Promise of Molecular Profiling
By
Caroline Helwick
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
February 2012, Vol 3, No 1
At the 2012 Gastrointestinal Cancers Symposium, Value-Based Cancer Care (VBCC) asked Al B. Benson, III, MD, FACP, Professor of Medicine, Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Immediate Past President, ACCC, and editorial board member of VBCC, to discuss the growing importance of molecular profiling in cancer care.
Read Article
Page 4 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma